Skip to main content

Nephrology Fellowship

NewYork-Presbyterian Queens

Nephrology Fellowship

Research Activity

Publications, 2006 - 2009

  • Spinowitz, B.S. and Pratt, R.D.  Epoetin delta is effective for the management of anaemia associated with CKD.  Current Medical Research and Opinions, Vol. 22(2006), pp 2507-2513.
  • Spinowitz, B.S., Coyne, D.W., Lok, C.E. et al. C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis When Administered Twice Monthly. Am J. Nephrol 2008;28:280-289
    Malluche, H.H., Claude Monier-Faugere, M., Wang, G., Frazao, J.M., Charytan, C., Coburn, J.W., Coyne, D.W., Kaplan, M.R., Baker, N., McCary, L.C., Turner, S.A., and Goodman, W.G.: AN ASSESSMENT OF CINACALCET HC1 EFFECTS ON BONE HISTOLOGY IN DIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM     Clinical Nephrology 2008 Apr;69(4):269-78.
  • Abu-Alfa, A.K., Sloan, L., Charytan, C., Sekkarie, M., Scarlata, D., Globe, D., and Audhya, P.: DARBEPOOETIN ALFA FOR IMPROVING AND MAINTAINING HEMOGLOBIN LEVELS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT RECEIVING DIALYSIS Curr Med Res Opin. 2008 Apr;24(4):1091-100. Epub 2008 Mar 6.
  • Block, G.A., Zeig, S., Sugihara, J., Chetow, G. M., Chi, E. M., Turner, S.A., Bushinsky, D.A: COMBINED THERAPY WITH CINACALET AND LOW DOSES OF VITAMIN D STEROLS IN PATIENTS WITH MODERATE TO SEVERE SECONDARY HYPERPARATHYROIDISM Nephrol Dial Transplant 2008 Jul;23(7):2311-8.
  • Spinowitz, B.S.: Anemia Management in Patients on Peritoneal Dialysis:  Efficacy &Safety Epoetin Delta Haematologica/THJ, 93/05 (May 2008)
  • Spinowitz, B.S., Kausz, A., Baptista, J., et al.: Safety and Efficacy of Ferumoxytol  for the Treatment of Liver Deficiency Anemia in Chronic Kidney Disease Patients (Accepted for Publication, JASN, 2008)
    Spinowitz, B.S., Germain, M., Benz, R., Wolfson, M., McGowan, T., Tang, K.L., Kamin, M.; for the Epoetin Alfa Extended Dosing Study Group: A Randomized Study Of Extended Dosing Regimens For Initiation Of Epoetin Alfa Treatment Of Chronic Kidney Disease Clin J Am Soc Nephrol 3:1015-1021, 2008.
  • Spinowitz, B.S., Kausz, A.T., Baptista, J., Noble, S.D., Sothinathan, R., Bernardo, M.V., Brenner, and Pereira, B. J.G.: Ferumoxytol for Treating Iron Defiency Anemia in CKD JASN, June 4, 2008.
  • Spinowitz, B.S.: Anermia Management in Patients on Peritoneal Dialysis: Efficacy and Safety of Epoetin Haematologica 2008 May;93(5):761-764, doi: 10.3324/haematol.10985
  • Kessler, M., Martinez-Castelao, A., Slamopoulos, K.C., Villa, G., Spinowitz, B., Dougherty, F.C., Beyer, U.: C.E.R.A. Once Every Four Weeks in Patients With Chronic Kidney Disease Not On Dialysis: the ARCTOS Extension Study Submitted for publication, Nephrology Dialysis Transplantation
  • Charytan, C., Spinowitz, B.S., Rachlin, P.,: THE SAFETY OF HIGH DOSE, 500 MG OVER FOUR (4) HOURS, IRON SUCROSE THERAPY IN ABULATORY AND HOSPITALIZED CKD PATIENTS In preparation for submission
  • Fishbane, S., Shapiro, W.B., Corry, D. B., Vicks. S.L., Roppolo, M., Rappaport, K., Ling, X., Goodman, W.G., Turner, S., and Charytan C.: CINACALCET HC1 AND CONCURRENT LOW-DOSE VITAMIN D IMPROVES TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS COMPARED WITH VITAMIN D ALONGE: THE ACHIEVE STUDY RESULTS Clinical Journal of the
  • American Society of Nephrology, Vo. 3, No. 6, pp 1718-1725, November, 2008.
    Chonchol, M., Locatelli, F., Abboud, H.E., Charytan, C., deFrancisco, A.L., Jolly, S., Kaplan, M., Roger, S.D., Sarkar, S., Albizem, M.B., Mix, T.C., Jubo, Y., Block, G.A.:  A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CINACALCET HC1 IN PARTICIPANTS WITH CKD NOT RECEIVING DIALYSIS  Am J Kidney Dis. 2009 Feb;53(2):197-207.

Abstracts

  • De Alvaro, F., Levin, A., Spinowitz, B.S. et al. C.E.R.A. Provides Improved Care in the Correction of Anemia in CKD Patients not on Dialysis With and Without Diabetes. (Presented at IDF, 2006).
  • Sprague, S., Charytan, C., et al: A PROSPECTIVE OBSERVATIONAL REGISTRY ASSESSING THE MANAGEMENT AND PROGRESSION OF SECONDARY HPT IN PATIENTS WITH CHRONIC KIDNEY DISEASE (ckd): METHODS AND OBJECTIVES National Kidney Foundation 2006 Spring Clinical Meetings, April 19-23, 2006, Chicago, Ill.
  • Shapiro, W., Martinez, C., Charytan, C., Horowitz, J., Tharpe, D., Droge, J., Ling, X., Belozeroff, V., Block, G., Sprague, S.: A PROSPECTIVE OBSERVATIONAL REGISTRY ASSESSING THE MANAGEMENT AND PROGRESSION OF SECONDARY HYPERPARATHYROIDISM (hpt) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD):Baseline Data ASN, San Diego, California, November 14-19, 2006.
  • Charytan, C.: A COMPARISON OF CINACALCET HC1 AND LOW-DOSE VITAMIN d Vs ESCALATING DOSES OF VITAMIN D ALONE—THE ACHIEVE STUDY ASN, San Diego, California, November 14-19, 2006.
  • Lu, Msl, Arslanian, J., Kopelman, R., Hammes, M., Liu, C., Cleveland, W., and Charytan, C.: INTERVENTION ANALYSIS: ACCESS SURVEILLANCE BY VENOUS ACCESS PRESSURE (VASCALERT, VA) vs FLOW (TRANSONIC, TS) ANS, San Diego, California, November 14-19, 2006.
  • Fishbane, S., Shapiro, W., Corry, D., Rappaport, K., Vicks, S., Ling, X., Maag, A., Turner, S., Charytan, C:  A COMPARISON OF CINACALCET HC1 AND LOW-DOSE VIATAMIN D vs ESCALATING DOSES OF VITRAMIN D ALONE – THE ACHIEVE STUDY, ASN, San Diego, California, November, 2006.
  • Charytan, C., Lu, Z., Arslanaian, J., Kopelman, R., Hammes, M., Liu, C., Cleveland, W.: (F-PO1041) INTERVENTION ANALYSIS: ACCESS SURVEILLANCE BY VENOUS ACCESS PRESSURE (VASCALERT, va) VS. FLOW (TRANSONIC, TS)  ASN, San Diego, California, November 17, 2006.
  • Shapiro, W., Martinez, Charytan, C., Horowitz, J., Tharpe, D., Droge, J., Ling, X., Belozeroff, V., Block, G., Sprague, S, for the Registry Study Group: (PUB358) A PROSPECTIVE OBSERVATIONAL REGISTRY ASSESSING THE MANAGEMENT AND PROGRESSION OF SECONDARY HYPERPARATHYROIDISM (HPT) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (ckd): BASELINE DATA
  • Spinowitz, B.S., Mann, J.,Mikhail, A. et al. Twice Monthly C.E.R.A. Provides Effective Stable Hemoglobin Maintenance in Dialysis Patients with Diabetes Mellitus. (Submitted to ADA,2007)
    Spinowitz, B.S., Germain,M., Benz, R. et al. Extended Dosing Regimens for Initiation of Epoetin Alfa for
  • Treatment of Anemia of Chronic Disease. (Presented at NKF, April 2007).
    Charytan, C., Corry, D., Roppolo, M., Ling, X., Droge, J., Fishbane, S.: ASSESSING THE USE OF THE CALCIMIMETIC CINACALCET WITH LOW DOSE VITAMIN VERSUS ESCALATING DOSES OF VITAMIN D ALONE IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (HPT) – THE ACHIEVE STUDY BASELINE DATA National Kidney Foundation Clinical Meeting, Orlando, Florida, April, 2007.
  • Spinowitz, B.S.,Vera-Lionch, M., Sofrygin, O. et al. Achievement of Target Hemoglobin with Ferumoxytol vs. Oral Iron in Anemic CKD Patients not Receiving Erythropoietin- Stimulating Agents (presented ASN 2007).
  • Fisbhane, S., Vicks, S. Ling, X., Turner, S., and Charytan, C.: CINCALCET WITH LOW DOSE VITAMIN D PROVIDES IMPORVED CONTROL OF PARATHYROID HORMONE, CALCIUM, AND CALCIUM-PHOSPHORUS PRODUCT IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM COMPARED WITH VITAMIN D ALONE Centtre Convencion Internacional Barcelona (CCIB), June 23, 2007.
  • Shapiro, W., Martinez, C., Charytan, C., Horowitz, J., Tharpe, D., Drage, J., Ling, X., Belozeroff, V., Goodman, W., block, G., and Sprague, S.: TREATMENT PATTERNS IN PATIENTS PROGRESSING THROUGH LATER-STAGE CHRONIC KIDNEY DISEASE (CKD); BASELINE DATA FROM A PROSPECTIVE OBSERVATIONAL REGISTRY National Kidney Foundation Clinical Meeting, April, 2008, Dallas, Tx
  • Malluche, H.H., Monier-Faugere, M.C., Wang, G., Frazao, J.M., Charytan, C., Coburn, D.W., Coyne, M.R., Kaplan, N., Baker, L.C., McCary, S.A. Turner and Goodman, W.G.: AN ASSESSMENT OF CINACALECET HC1 EFFECTS ON BONE HISTOLOGY IN DIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM Clinical Nephrology, Volume 68, No. 4/2008 (April).
  • Raayasa, S, Spinowitz, B., Charytan, C.: CROHN’S DISEASE AND SECONDARY AMYLOIDOSIS: A RENAL PERSPECTIVE Residents and Fellows Day, Lang Research Center, NewYork-Presbyterian Queens, Flushing, N.Y., May 14, 2008.
  • Bhar, A., Mir, M., Sabayev, V., Charytan C.: ESRD PATIENTS REQUIRING RRT IN MICU: OUTCOMES AND SERUM PROGNOSTIC MAREKRS Residents and Fellows Day, Lang Research Center, NewYork-Presbyterian Queens, Flushing, N.Y., May 14, 2008.
  • Chang, J.J., Ghith, T., Spinowitz, B.S., Charytan, C.: SAFETY OF A 500 MG IRON SUCROSE 4-HOUR INFUSION FOR THE CORRECTION OF IRON DEFICIENCY ANEMIA, Residents and Fellows Day, Lang Research Center, NewYork-Presbyterian Queens, Flushing, N.Y., May 14, 2008.
  • Charytan, C:, Miller, R.T., Lu, J., Kubo, Y., Lopez., Horowitz, J.: HEALTH RELATED QUALITY OF LIFE (HRQOL) IN DIALYSIS PATIETNS TREATED FOR SECONDARY HYPERPARATHYROIDISM (SHPT). American Society of Nephrology Annual Meeting, Philadelphia, PA., November, 2008.
  • Fishbane, S., Wetmore, J., Moustafa, M., Martinez, C., Stewart, T., Ling, X., Goodman, W., Charytan, C.: EFFICACY OF TREATMENTS TARGETING THE CALCIUM-SENSING RECEPTOR (CaR) AND VITAMIN D RECEPTOR (VDR) IN CONTROLLING PARATHYROID HORMONE (PTH) IN HEMODIALYSIS PATIENTS Am Dietetic Assoc Meeting, October, 2008.
  • Levin, N.W., Schmidt, R., Spinowitz, B.S., et al: C.E.R.A. Has Similar Safety and Tolerability as Epoetin or Darbepoetin During Hemoglobin Maintenance in Dialysis Patients : Pooled Data from 4 Phase III Vials (Submitted to ICA, 2008)
  • Charpentier, B., Olivares,J., Beyer, U., and Spinowitz, B.:  C.E.R.A. Maintains Stable Haemoglobin Levels in dialysis Patients Regardless of Administration Route (IV or SC) (Presented at EDTA 2008)
    Spinowitz,B, Kausz, AT, Dioguardi, J et al Ferumoxytol is Safe in all Stages of Chronic Kidney Disease ( presented at NKF 2008)
  • Spinowitz, B.S.:Hemoglobin Response Following Ferumoxytol AdministrationIn CKD Patients: Impact Of Baseline Hemoglobin And Iron Parameters Accepted for presentation, ASN 2008, Philadelphia, PA
  • Spinowitz, B.S., Milich, L., Chang, M., Brenner, L.:Gastrointestinal Tolerability Of IV Ferumoxytol And Oral Iron Therapy In Patients With Iron Deficiency in Anemia and Chronic Kidney Disease Submitted to American Society of Hematology, 2008./li>

Studies

Dr. Charytan:

  • A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease including Assessment of Quality of Life
  • A Randomized, single-Blind, Placebo-Controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects with Chronic Kidney Disease Not Requiring Dialysis
  • A Phase2 Randomized, Double-Blind, Placebo-controlled Study of FG-3019 in Subjects with Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blocker (ARB) Therapy

Dr. Spinowitz:

  • A 52-Week, Multi-Centered, Double-Blind, Randomized, Placebo-Controlled Phase IIb Trail to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients with Type 2 Diabetes and Chronic Kidney Disease with an eGFR of 2- 45 mL/min/1.73m2
  • A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects with Stage 3 Chronic Kidney Disease